82 results about "Distant metastasis" patented technology

The invention discloses a method for establishing a nasopharyngeal carcinoma distant metastasis predicting model. The method comprises the steps of selecting a nasopharyngeal carcinoma tumor pathological slice digital image with known metastasis information as a training set of a deep learning algorithm; obtaining a processed nasopharyngeal carcinoma tumor pathological slice digital image; training and optimizing the processed nasopharyngeal carcinoma tumor pathological slice digital image and patient clinical information; establishing a function relation formula between a distant metastasis risk of a nasopharyngeal carcinoma patient and a score S, and performing interval classification on a P value with distant metastasis and the P value without distant metastasis. The invention providesthe method for establishing the nasopharyngeal carcinoma distant metastasis predicting model, wherein a deep learning algorithm is applied in pathology, and artificial intelligence technology is utilized for realizing establishment of a tumor prognosis predicting model.

The invention relates to an application of an esophageal squamous cell carcinoma primary tumor strain CH-H-1 in a mammal for producing esophageal squamous cell carcinoma cells. The primary tumor strain CH-H-1 disclosed by the invention can realize multiple passages through NOD / SCID mice, has significance for solving the bottleneck that the current treatment of the esophageal squamous cell carcinoma can not avoid distant metastasis, and is an ideal object for fundamental research on the esophageal squamous cell carcinoma and clinical early application.

The invention discloses a nasopharyngeal carcinoma distant metastasis predicting system based on a deep learning algorithm. The predicting system comprises the following modules of: an image acquisition module, an image preprocessing module, a patient information collecting module, a distant metastasis predicting module based on the deep learning algorithm, and a predicting information output module. The system of the invention realizes risk predicting to nasopharyngeal carcinoma distant metastasis of a nasopharyngeal carcinoma patient. Compared with an analysis-diagnosis-treatment mode in which traditional molecular biological technology and gene sequencing and the like are used as main means, the system has advantages of improving efficiency in acquiring a diagnosis result and realizingpredictive judgment which cannot be independently performed by a clinical doctor.

The invention discloses a biomarker reagent used for detecting a breast cancer state, which is an ultra high resolution fracsimile (UHRF 1) gene. The UHRF 1 gene is closely related to distant metastasis capacity of a breast cancer; the UHRF 1 gene is used as a biomarker predicting the distant metastasis capacity of the breast cancer, and the malignancy degree of the breast cancer can be predicted more accurately in a more individualized manner compared with transferring and prognosis of the breast cancer judged by the conventional pathological type.

The invention provides an ELISA (enzyme linked immunosorbent assay) kit for detecting endothelial cell specific molecule-1 (ESM-1) of a tumour marker, wherein the kit comprises (1) a coated antibody, wherein the coated antibody is a mouse anti-human ESM-1 antibody; (2) a detection antibody, wherein the detection antibody is a biotinylated goat anti-human Endocan antibody; (3) an enzyme linked antibody, wherein the enzyme liked antibody is a rabbit anti-goat IgG (immunoglobulin G) marked by a horseradish peroxidase; (4) a human Endocan standard substance; and (5) a colour development substrate of the enzyme linked antibody. By the kit provided by the invention, the early diagnosis rate of gastric cancer can be improved under a relatively small wound; the biomarker is an independent prognostic factor and is relevant to vessel invasion, distant metastasis and general classification of gastric cancer, so that prognosis can be predicted, states of the illness can be monitored, and treatments can be guided.

The invention discloses a tumor-associated sequence, a tumor-associated long non-coding RNA (lncRNA) and application of the tumor-associated sequence. lncRNA GMAN (gastric cancer metastasis associatedlong noncoding RNA) has relatively high expression in gastric cancer and particularly has remarkably high expression in samples of patients with M1-stage gastric cancer generating distant metastases,and the high expression of the GMAN is remarkably related to poor prognosis of the patients with the gastric cancer. A research shows that the GMAN plays an important role in occurrence and development of the gastric cancer; the GMAN can be used for remarkably promoting invasion and metastasis of gastric cancer cells. A therapeutic experiment of CRISPR / Cas9 shows that the GMAN, in particular to an MFR (mannosylfucosyl receptor) segment of the GMAN, can be used for effectively inhibiting the metastasis of the gastric cancer and can serve as a novel strategy for controlling the metastasis of tumors clinically.

The invention relates to an esophageal squamous cell carcinoma primary tumor line CH-H-2 which is used in mammals to produce esophageal squamous cell carcinoma cells. The primary tumor line CH-H-2 can be passed by NOD / SCID mice for multiple times, is significant in solving the inevitable bottleneck problem of distant metastasis in the current esophageal squamous cell carcinoma treatment, and is an ideal object for the basic research and clinical early application of esophageal squamous cell carcinoma.

A molecular marker for esophageal cancer is disclosed and is an FXR1 gene and / or an expression product of the FXR1 gene. The FXR1 gene is significantly highly expressed in esophageal cancer tissue, and can be adopted as an esophageal cancer molecular marker for esophageal cancer diagnosis. The highly expressed FXR1 gene is closely related to poor prognosis and distant metastasis of patients with esophageal cancer so that the FXR1 gene can be adopted as a prognosis marker for esophageal cancer and can provide effective information for esophageal cancer distant metastasis, prognosis evaluation and treatment effect monitoring. An expression inhibitor of the FXR1 gene is disclosed by the invention and includes siRNA and / or shRNA, has good jamming effects when being used for suppressing FXR1 gene expression and has a potential for application in clinical genetic treatment. The invention further discloses a cell strain capable of stable knock-down of the FXR1 gene. The cell strain is an esophageal cancer cell capable of stable low expression of the FXR1 gene, thus facilitating further research of functions of the FXR1 gene.

The invention discloses a preparation method and applications of hollow gold nanospheres modified by CpG oligodeoxynucleotide. Cobalt chloride is subjected to reduction by adopting sodium borohydride,thus cobalt nanoparticles are obtained, cobalt nanoparticles are adopted for carrying out reduction on chloroauric acid, and thus hollow gold nanospheres are prepared; CpG oligodeoxynucleotide, a surfactant and a buffer solution are added into a solution of the hollow gold nanospheres, shaking culture is carried out, and thus the hollow gold nanosphere material modified by CpG oligodeoxynucleotide is obtained. According to the technical scheme, by utilizing the property that the hollow gold nanospheres have the large loading capacity, CpG is loaded through the self-assembly effect, the synthesis method is simple, and the method is suitable for large-scale production and application; the cell uptake capacity of CpG oligodeoxynucleotide can be enhanced, and the biocompatibility is good; thehollow gold nanospheres modified by CpG oligodeoxynucleotide have the near-infrared surface plasma adsorbing effect, the primary tumor is eliminated by utilizing the photothermal ablation effect, a tumor antigen is generated in situ, under the promoting of CpG oligodeoxynucleotide, the antitumor immunity of the whole body is induced, and the distant metastasis tumor is further treated.

The invention provides a novel 64Cu labeled PSMA targeted inhibitor as well as a preparation method and an application thereof. The 64Cu labeled PSMA targeted inhibitor is a 64Cu labeled NODA-PSMA conjugate; the inhibitor, when used as a prostate PET molecular probe, is good in stability and good in developing effect; the inhibitor is conducive to diagnosis and accurate staging of early prostate and is beneficial for guiding surgical resection; and the inhibitor can offer a diagnosis basis for recurrence as well as local and distant metastasis of the prostate; therefore, the inhibitor has an important clinical application value.

An improved autovaccination method designed to prevent or treat various neoplastic diseases by inducing a systemic immune response against a tumor and its remote metastases, consisting of the induction of an immunogenic cell death in one or more targeted tumor sites with local radiation therapy, cryotherapy, heat, chemotherapy or various other treatments, followed by intratumoral / peritumoral injection of dsRNAs (poly-ICLC in particular) in the same tumor site.

The invention discloses a tyrosine kinase inhibitor. A chemical name of the tyrosine kinase inhibitor is 1-(2-chloro-4-((6,7-dimethoxyquinoline-4-yl)oxy)phenyl)-3-(4-fluorophenyl)carbamide and a structure is shown as a formula (I). Meanwhile, the invention further discloses application of the tyrosine kinase inhibitor. The tyrosine kinase inhibitor provided by the invention can be used for effectively inhibiting enzymatic activity of VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) and VEGFR3 (Vascular Endothelial Growth Factor Receptor 3) and can be used for effectively treating diseases which are regulated and controlled through tyrosine kinase and are related with anomaly of a tyrosine kinase signal transduction pathway, and the diseases comprise cancers of breasts, respiratory tracts, brains, reproductive organs, digestive tracts, urinary tracts, eyes, livers, skin, heads and / or necks and distant metastasis of the cancers, lymphoma, sarcoma, leukemia and the like.

Human breast carcinoma SK-BR-3 cell strain as source cell for building train adapted by the invention is continuously inoculated on female NOD / SCID mouse mammary gland fat pad and filtered in pressure of low dose chemotherapy drug tail intravenous injection to build human breast carcinoma cell line SK-3rd rich in tumour breast carcinoma stem cell. The proper of knub stem cell in the cell is increased greatly comparing with non NOD / SCID vivo passage source cell. The formation rate of saccule and the number of cell in the saccule are increased greatly in case of cell suspension culture. The ratio of undifferentiation cancer cell is reduced but is higher evidently than source cell in process of SK-3rd saccule cell inducing differentiation. The saccule cell formed from SK-3rd cell has carcinoma stem cell phenotype which gradually dies out in process of differentiation. NOD / SCID mouse orthotopic transplantation has high tumour-forming rate, high long-distance transferring rate, short tumour-forming periodic time and less number of cells needed by tumour-forming. The invention is an ideal mould for studying breast carcinoma stem cell and has wide applications foreground for disclosing generation mechanism of breast carcinoma and neoplastic treat.

The invention relates to the field of medical treatment, in particular to a storing and recording method and classified collecting box for organ specimens and lymph node specimens in surgical operations. The classified collecting box for the organ specimens and the lymph node specimens in the surgical operations comprises a classification box I and a classification box II. The upper surface of the classification box I is divided into a primary lesion storing area and a distant metastasis storing area. An organ specimen storing tank is arranged in the primary lesion storing area. An anatomical atlas is arranged on the upper surface of the classification box II, and a plurality of lymph node specimen storing tanks are formed in the upper surface of the classification box II. The storing and recording method for the organ specimens and the lymph node specimens in the surgical operations comprises the steps that the classified collecting box for the organ specimens and the lymph node specimens in the surgical operations is adopted; and taken-down distant metastasis tissue is placed into distant metastasis storing tanks, then corresponding marks are pasted to the positions near the distant metastasis storing tanks, and the specific sampling positions of the distant metastasis tissue in corresponding sampling organs are marked on mark pasters. Comprehensive and detailed recording can be carried out on related information of the specimens in the surgical operations.

A method for predicting the likelihood of locoregional recurrence (LRR) and / or distant metastasis in a subject with breast cancer following mastectomy and / or breast conserving surgery, comprising: measuring the expression level of at least one gene in a sample isolated from the subject; and deriving a score based on the measured expression level of the at least one gene, wherein the at least one gene is selected from a group consisting of TRPV6, DDX39, BUB1B, CCR1, STIL, BLM, C16ORF7, TPX2, PTI1, TCF3, CCNB1, DTX2, PIM1, ENSA, RCHY1, NFATC2IP, OBSL1, and MMP15, and wherein the derived score provides an indication of the likelihood of LRR and / or the likelihood of distant metastasis in the subject.

The invention discloses an application of EB virus encoded microRNA BART10 (EBV-miR-BART10) in preparing a prediction preparation for recurrence and metastasis of nasopharyngeal carcinoma. The research proves that the expression level of EBV-miR-BART10 in the nasopharyngeal carcinoma tissue is in positive correlation with the lymphatic metastasis and the distant metastasis of the nasopharyngeal carcinoma patient; if the expression of the EBV-miR-BART10 in the nasopharyngeal carcinoma tissue is up-regulated, the nasopharyngeal carcinoma patient with higher EBV-miR-BART10 expression have larger possibilities of recurrence and metastasis than the nasopharyngeal carcinoma patient with lower EBV-miR-BART10 expression, and the prognosis is worse, therefore, the application of the expression of the EBV-miR-BART10 in the predication of recurrence and metastasis of the nasopharyngeal carcinoma patient can provide powerful biomolecular basis for the prognosis of the nasopharyngeal carcinoma patient, and thus the application method has profound clinical significances and important popularization and application prospects.

The invention discloses a cancer marker, wherein the cancer is a prostate cancer, and the cancer marker is an expression product of an APMAP gene and / or an APMAP gene. The APMAP gene is highly expressed in prostate cancer, which can be used for early diagnosis of prostate cancer, and has the advantages of specificity and high sensitivity. The high expression of APMAP gene is closely related to thepoor prognosis, distant metastasis and lymph node metastasis of prostate cancer, suggesting that APMAP gene can be used as a prognostic marker to provide effective information for the metastasis diagnosis, prognosis evaluation and treatment effect monitoring of prostate cancer. The invention discloses an expression inhibitor of an APMAP gene, comprising siRNA and / or shRNA, which has good interference effect on the expression of the APMAP gene, and has the application potential of clinical gene therapy. The invention discloses a cell strain of stable knockdown APMAP gene, which is favorable for realizing further research on gene function.

The invention provides circPTEN1 for a tumor treatment target and a diagnosis biomarker and application of circPTEN1, and belongs to the technical field of biology. A nucleotide sequence of the circPTEN1 for the tumor treatment target and the diagnosis biomarker is shown as SEQ ID NO: 1, and the circPTEN1 is a novel circular RNA formed by reversely splicing the first exon to the fifth exon of PTEN mRNA. High expression of the circPTEN1 remarkably inhibits migration and invasion of colorectal cancer cells, the expression level of the circPTEN1 is in negative correlation with lymph node metastasis and distant metastasis of a colorectal cancer patient, and prognosis of the colorectal cancer patient with low expression of the circPTEN1 is poor. Therefore, the circPTEN1 is applied to tumor treatment, tumor diagnosis and tumor prognosis evaluation as the tumor treatment target and the diagnostic biomarker, and a new thought and a new strategy are provided for treatment-related drugs and diagnostic products.

The invention discloses a lung cancer TNM staging acquisition method. The method comprises the following steps of identifying a target nodule in a medical image; acquiring long and short paths of thetarget nodule, and generating T stages at least based on the long and short path; identifying abnormal lymph nodes in the medical image, and generating N stages by judging whether the abnormal lymph nodes have metastasis or not; acquiring whether the target nodule has distant metastasis or not, and generating M stages according to whether the target nodule has distant metastasis or not; and generating a TNM stage according to the T stage, the N stage and the M stage. According to the method, a nodule recognition model, a nodule segmentation model and a lymph node metastasis recognition model are trained, the information outputted by the models is utilized to automatically generate a T stage and an N stage, and whether distant metastasis information is generated into an M stage or not is judged in combination with doctor input or by accessing medical records and the like. According to the method, TNM staging generation efficiency is effectively improved, a doctor can conveniently and quickly know the illness state of a patient, and diagnosis efficiency is improved.

The invention provides a papillary thyroid carcinoma distant metastasis mutation predicting model, a predicting model method and a predicting model system. The papillary thyroid carcinoma distant metastasis mutation predicting model realizes high predicting accuracy which is higher than that of a currently reported model. Furthermore the papillary thyroid carcinoma distant metastasis mutation predicting model has high sensitivity and high specificity. Furthermore researching of the invention proves a fact that TERT starter mutation has no evident correlation with distant metastasis, and furthermore chr22q loss and gene fusion are remarkably correlated with distant metastasis. The samples of the invention are obtained from Chinese people, and foreign researching samples are obtained from the Western country people. Therefore the researching result of the invention has higher application value for the Chinese people.

The invention relates to a medical information processing method. The method comprises the steps: obtaining first to third recognition information based on the AI recognition of first medical information, second medical information and third medical information, wherein the first recognition information comprises the tumor primary lesion condition, the second recognition information comprises theregional lymph node fatigue condition, and the third identification information comprises a remote transfer condition; and outputting interpretation information according to the first recognition information, the second recognition information, the third recognition information and standard information. The medical information processing system is linked to a medical diagnosis business data systemthrough a corresponding data interface, and comprises: an AI identification module configured to obtain identification information including different pathological information based on different medical information, and an analysis module used for obtaining the interpretation information according to the different identification information and the standard information. Through the embodiments ofthe invention, intelligent inference of corresponding diagnosis information can be realized, the working efficiency of doctors is improved, and the clinical data preparation cost is reduced.

The present invention provides genetic markers, SOX5 and SPARC, for distant metastasis and poor prognosis of detection of the high risk potential for cancer patients. In addition, the present invention also provides a method to predict the risk potential for cancer patients with distant metastasis and poor prognosis. This method comprises obtaining a tissue sample from a patient, evaluating the expression levels of the SOX5 and / or SPARC genetic markers in the sample; and comparing the expression levels of genetic markers with those of non-cancerous tissues. The patient is determined to have the high risk of distant metastasis or poor prognosis when the expression level of SOX5 is higher, or when the expression level of SPARC is lower, than that of non-cancerous tissue. Furthermore, the identified genetic marker SOX5 and / or SPARC can also be used for cancer targeted therapy, because down regulation of SOX5 and / or up regulation of SPARC expression in NOD-SCID can retard tumor growth and inhibit cell proliferation, migration, invasion and metastasis.

The invention relates to the field of biomedicine. More specifically, the present invention relates to an intestinal cancer peritoneal metastasis prediction model and a construction method thereof. The intestinal cancer peritoneal metastasis prediction model is as follows: Model=32.892 + 1.51 * CT_stage + 1.884*tumor location + 20.447*distant metastatic sites - 19.898*thickened greater omentum - 20.222*pelvic nodules, wherein the CT_stage is a T stage, the tumor location is a tumor site, the tumor location is a tumor site, the distant metastatic sites are used as far transfer parts, the thickened greater omentum is used for thickening the omentum majus, and the pelvic nodules are pelvic implant nodules. The intestinal cancer peritoneal metastasis prediction model is high in prediction accuracy and has high sensitivity and specificity.

The invention belongs to the medical technology field, in particular relating to a method for enhancing high intensity focused ultrasound (HIFU) induced anti-tumor immune response. On the premise of having no change on the existing HIFU oncotherapy ultrasound strength, the method utilizes a sparse scanning strategy to enable tumor tissue heat denaturation spots generated by single HIFU treatment to have a proper spacing so as to reserve tissues around each heat denaturation area. The method can enable the tumor issues to have stronger capacity of recruiting and activating interdigitate cells and inducing out stronger anti-tumor immune response while having no influence on primary tumor thermal ablation curative effect by HIFU, thus killing epibiotic viable cells and preventing and curing tumour distant metastases. The method can improve overall tumor curative effect of HIFU and shorten curative time.

The invention discloses a tyrosine kinase inhibitor. A chemical name of the tyrosine kinase inhibitor is 1-(2-chloro-4-((6,7-dimethoxyquinoline-4-yl)oxy)phenyl)-3-(4-fluorophenyl)carbamide and a structure is shown as a formula (I). Meanwhile, the invention further discloses application of the tyrosine kinase inhibitor. The tyrosine kinase inhibitor provided by the invention can be used for effectively inhibiting enzymatic activity of VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) and VEGFR3 (Vascular Endothelial Growth Factor Receptor 3) and can be used for effectively treating diseases which are regulated and controlled through tyrosine kinase and are related with anomaly of a tyrosine kinase signal transduction pathway, and the diseases comprise cancers of breasts, respiratory tracts, brains, reproductive organs, digestive tracts, urinary tracts, eyes, livers, skin, heads and / or necks and distant metastasis of the cancers, lymphoma, sarcoma, leukemia and the like.

The invention discloses a novel target PCDHB2 for breast cancer osseous metastasis diagnosis and treatment. The significantly high expression of the PCDHB2 in multiple subtype breast cancer tissue with the osseous metastasis is determined, the high expression of the PCDHB2 in all kinds of breast cancer tissue, BasL breast cancer tissue and other types (LumA type, Lumb type and Her2 type) of breastcancer tissue indicates the occurrence of earlier osseous metastasis, the PCDHB2 is not associated with distant metastasis of other parts of the breast cancer (brain, lung and liver), and it is suggested that the PCDHB2 can more specifically predict the occurrence of the breast cancer osseous metastasis. The down-regulation of PCDHB2 expression can significantly inhibit osseous metastasis of breast cancer cells and inhibit anoikis, migration and invasion resisting capacities of the breast cancer cells, and the PCDHB2 is the novel target of diagnosis, prognosis and treatment of breast cancer osseous metastasis.

The invention discloses a lung cancer TNM staging acquisition method and device. The method includes identifying a first target nodule in a first medical image; matching the first target nodule in a second medical image, and obtaining a second target nodule in the second medical image; acquiring long and short diameters of the second target nodule, and generating T stages at least according to thelong and short diameters of the second target nodule; identifying abnormal lymph nodes in the first medical image and generating N stages by judging whether the abnormal lymph nodes have metastasis or not; identifying whether the first target nodule in the first medical image has distant metastasis or not, and generating M stages according to whether the first target nodule has distant metastasisor not; and generating a TNM stage according to the T stage, the N stage and the M stage; wherein the first medical image and the second medical image are different modal medical images for the samepatient and the same part. According to the scheme, the TNM staging generation efficiency is effectively improved, doctors can conveniently and quickly know the illness state of a patient, and the diagnosis efficiency is improved.

An estrogen-regulated gene sequence SHON has been characterised, and found to be a novel oncogene in mammary carcinoma and significantly associated with estrogen and progesterone receptor expression in breast cancer. The present invention encompasses methods for predicting the responsiveness to endocrine therapy for breast cancer and providing a prognosis for disease-free and / or distant metastasis-free survival of a cancer patient.

The invention relates to the medical field, in particular to a method for storing and recording surgical organs and lymph node specimens and a classification collection box. A surgical organ and lymph node specimen classification collection box includes a staging box I and a staging box II; the upper surface of the staging box I is divided into a primary tumor storage area and a distant metastasis storage area, and the primary tumor storage area is provided with an organ Specimen storage tank, the upper surface of the staging box II is provided with anatomical atlas, and the upper surface of the staging box II is also provided with a plurality of lymph node specimen storage tanks; a method for storing and recording surgical organs and lymph node specimens uses surgical organs and Lymph node specimen classification collection box; put the removed distant metastatic tissue into the distant metastatic storage tank, and then paste the corresponding label near the distant metastatic storage tank, and mark the distant metastatic tissue on the label Specific sampling locations in corresponding sampling organs. The invention can comprehensively and detailedly record the related information of the surgical specimen.

The present invention relates to methods which make possible to assess and / or prognose a cancer disease, the metastatic behaviour of a cancer disease and / or the occurrence of a relapse of cancer. In particular, the methods of the invention make possible to assess and / or prognose the occurrence of cancer metastasis, in particular distant metastasis. Preferably, the methods of the invention allow to discriminate malign from benign conditions.